Given the ineffectiveness of standard high-dose chemotherapy and CBL mutation presence, combined targeted therapy was started on Day 46 after diagnosis (trametinib 0.25 mg/day + ruxolitinib 15 mg/day) in an attempt to target the hyperactivated pathways normally inhibited by CBL and to reduce the tumor mass before HSCT. Here, CBL is linked to neoplasm.